MSCT proves acceptable for selecting pancreatic cancer patients for surgery

Article

Multislice CT is an acceptable alternative to endoscopic ultrasound for identifying which pancreatic lesions can be treated surgically, according to a study from Indiana University.

Multislice CT is an acceptable alternative to endoscopic ultrasound for identifying which pancreatic lesions can be treated surgically, according to a study from Indiana University.

Four-slice CT showed accuracy comparable to endoscopic ultrasound in detecting resectable pancreatic tumors, said lead author Dr. John DeWitt, an assistant professor of medicine at the IU School of Medicine.

In fact, a person having a high-quality CT scan showing a completely resectable mass can forgo endoscopic ultrasound for confirmation altogether, DeWitt said.

In a prospective study, DeWitt and colleagues examined 120 patients with confirmed or suspected pancreatic cancer. The subjects underwent endoscopic ultrasound followed by quadslice CT with dual-phase imaging. Results were published in the November issue of the Annals of Internal Medicine.

Of 80 patients with confirmed cancer, 66% qualified for surgery. Although endoscopic ultrasound was generally more accurate than MSCT for detection and staging, the differences were not significant enough to win DeWitt's support for the modality for assessing disease resectability.

Ultrasound scored a 98% accuracy rate for detecting pancreatic tumors, compared with 86% accuracy for MSCT, and ultrasound staging was 67% accurate, compared with a dismal 41% for MSCT. However, only four percentage points separated ultrasound's 92% accuracy rate for identifying viable tumor candidates and the 88% rate for MSCT. Additionally, MSCT correctly identified 64% of the 28 unresectable tumors compared with 68% for ultrasound.

The noninvasiveness of MSCT is a big advantage, according to DeWitt. It does not require sedation or the insertion of an endoscope, making the technique less invasive than endoscopic ultrasound and more attractive for determining lesion resectability.

"MSCT should be the initial test of choice in patients with suspected pancreatic cancer," he said.

Some of the limitations of the study included a small sample size and the fact that radiologists and sonographers were not blinded to previous radiographic information. Further comparative studies using 32- or 64-slice scanners with multiplanar reconstruction are needed, according to DeWitt.

For more information from the online Diagnostic Imaging archives:

MDCT boosts staging of pancreatic cancer

Pancreatic MR defines ducts, pinpoints disease

Fast spiral CT has edge in imaging pancreatic cancer

Newsletter

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Recent Videos
SNMMI: Emerging PET Insights on Neuroinflammation with Progressive Apraxia of Speech (PAOS) and Parkinson-Plus Syndrome
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
Related Content
© 2025 MJH Life Sciences

All rights reserved.